Colon capsule endoscopy

Regular Off Off

A colon capsule is a painless procedure which uses a camera to examine the large bowel (colon). Your bowel takes away the waste your body does not need.

The colon capsule test is a capsule which you swallow, and it contains two tiny cameras inside. It is around the size of a large vitamin tablet. The cameras take pictures of the lining of the bowel to look for any problems or signs of disease. This test can be used instead of a colonoscopy.

Why would I have this test?

There are a number of reasons why you may need an examination of your large bowel (colon):

  • you have symptoms like a change in your bowel habit or blood in your stool (poo)
  • you need a test to check for bowel diseases which you may be at risk of developing
  • you’ve been referred for this test because you were unable to have a colonoscopy

Patients with pacemakers or internal electro-medical devices, or pregnant women should not have this test.

Before the test

For this test to work well your bowel needs to be very clean so the cameras get the best pictures.

Please stop any iron tablets for 7 days prior to procedure.

For 3 days before your test you will be asked to change your diet, and to have only the type of food and drinks which help soften your stools (poo). Please look at the table below which has all the foods that are allowed and those that should be avoided in the three days before your test.

Please remember that if we do not get good enough views of the colon we may need to repeat the test with all the bowel preparation. Please only eat foods from the permitted side of the table.

We ask that you eat no more solid food after 10am the day before the procedure. You may continue to take clear fluids until 6am the day of the procedure.

You will need to take some strong laxatives on the day before your test and again on the morning of the test. These laxatives and instruction letter should have been sent to you along with this leaflet. Please contact the endoscopy department if you have not received them.

We will ask you to take the first dose of bowel preparation at 7pm the night before the procedure. We encourage lots of clear fluids alongside this.

On the day of the test

You will need to take the second dose of bowel preparation at 6am. Please do not drink anything further after this.

You should attend the endoscopy department at Southmead hospital - Gate 13, usually at 10am. Your appointment will last around 30 minutes. There are no effects from the test which would stop you driving to or from the clinic.

A trained nurse will check you’re ready to start the test, answer any questions you may have and go through a consent form with you. The nurse will fit you with a special belt and receiver which you can wear underneath your clothes.

You’ll be given the capsule to swallow. The receiver will capture the pictures of your bowel which are sent wirelessly from the capsule. You can then return home.

When you are back at home

You wear the belt and receiver at home during the whole test which lasts around 6 hours. It is recommended that the belt is worn until bedtime or until the battery runs out.

The capsule will work its way through your intestines but in order to get a view of all of your bowels, throughout the day of your test you’ll be asked to take more laxatives which act as a “booster” to help move the capsule through your bowel. These will be given to you to take home when you attend to swallow the capsule. You may not need to take all of them depending on when you pass the capsule out in into the toilet.

  • Booster 1 – this should be taken 2 hours after swallowing the capsule. The 2 ingredients are:
    • 50ml Gastrografin and
    • 30ml Fleet Phospho-soda.
    • Please measure out and mix both of these with 1 litre of cold water and drink. You can add some light coloured cordial or squash, if you wish, to the mixture.
  • Booster 2 – This should be taken 3 hours after the first booster if the capsule has still not been excreted. The measurements are different to Booster 1. This time:
    • 50ml Gastrografin and
    • 15ml of Fleet Phospho-soda.
    • These are mixed with 500ml of cold water (cordial can be added again as above)
  • Booster 3 – if the capsule has not been excreted 2 hours after the second booster, you will need to insert a suppository in to your bottom (rectum) to help it pass. This is labelled as booster 3 and is a bisacodyl suppository.

The capsule will normally pass out of your bowel in the afternoon or evening before you go to bed, and will just be flushed safely away down the toilet. Do not take any further boosters once you have seen the capsule pass. When the capsule has been passed, you can remove the belt and receiver and get back to normal activities.

You can resume eating and drinking as normal, either once you have seen the capsule pass, or after you use the suppository (booster 3). Before then, the fluid taking with the laxatives and the boosters will keep you from getting dehydrated.

If you do not see the capsule pass, remove the belt once the battery has become exhausted.

If you have any problems on the day of the test, please contact the endoscopy department on:

After the test

The day after the test you’ll be asked to return the belt and receiver back to the endoscopy department. The pictures from your test are uploaded from your recorder once it is returned. These pictures are then made into a video which is looked at by a trained doctor or nurse.

Further tests

Your consultant will decide whether you need another test based on your colon capsule report. For the majority of patients who have the colon capsule test, nothing will be found which leads them to have any further tests.

For patients who do need another test, this is usually because:

  • the capsule has found something that needs further investigation
  • the bowel wasn’t clean enough for the camera to record clear pictures
  • the capsule didn’t make it all the way around the large bowel before the battery ran out

This further test may be a colonoscopy, or a shorter camera test called a flexible sigmoidoscopy. These tests are usually needed to either treat something found by the capsule or to take a sample from the lining of the bowel to get a diagnosis.

If you have either of these tests you will have to take more laxatives before you have the test. A follow up test may be done urgently depending on what is found on the colon capsule.

Are there any risks or complications with the colon capsule test?

Most patients who decide to have a colon capsule test have no problems. If there is a problem, it’s usually because of the laxatives you take before the test. The strong laxatives can cause a few patients to be sick and become dehydrated. If this does happen, you’ll feel better once you stop taking the laxatives.

Complications related to the capsule itself are rare. A very small number of patients may have some difficulty swallowing the capsule, but you’ll be asked about any issues with swallowing before you start your test. Additionally there is a very small risk of the capsule getting stuck in your intestines.

What if the capsule doesn’t pass through the bowel at the end of the test?

It may just be delayed and this is nothing to worry about. The capsule might get stuck on a narrow section of the bowel, if this happens then that’s usually an answer for why the test was needed.

The capsule very rarely causes any blockage which needs further treatment.

Following the test, you must not have an MRI test unless the capsule has been passed. If there is any doubt about this, you might need an X-ray to show that the capsule has been passed. 

Foods allowed before your test

Please follow the low residue diet above for 3 to 4 days, instead of just the day before which may be stated in the leaflet of the bowel preparation you are provided with.

Food typeFood allowedFood to avoid 
Fruits / Vegetables / NutsFruit juice (strained with no bits). Only one glass a day if 
possible. 
Potatoes (without skins). 
All fruit and vegetables.
Potato skins, potatoes cooked in fats.
Crisps, nuts, chutneys, and pickles.
Bread and cereals Cereals e.g. Rice crispies, cornflakes.
White bread and bread products.
White rice, ground rice, semolina, tapioca.
White pasta and flour, corn flour.
High fibre cereals, branflakes, weetabix.
Brown rice/pasta/flour, pastries.
Brown, wholemeal, granary breads.
Porridge oats, muesli, fruit and fibre.
Cakes and biscuits White flour crisp breads, meringue.
Plain fat free cakes, scones, buns.
Plain biscuits, rich tea.
Cakes with cream, fat, jam with seeds, fruit or nuts.
Ryvita, shortbread.
Biscuits containing high fibre/ fruit/nuts.
Meats and alternatives Lean meats, poultry, liver, kidney.
Quorn, tofu.
Fatty meats, poultry skin, duck, goose.
Processed meat, luncheon meat, corned beef, black pudding, salami, sausages, and beef burgers.
Pate, meat pies.
Peas, beans, lentils.
 
FishWhite fish, smoked haddock, trout, salmon, tuna in brine, shell fish, prawns.Fried or oily tinned fish, herring, kippers, mackerel, sardines, pilchards, anchovies.
EggsBoiled, poached or scrambled.Fried eggs, omelettes, or scotch eggs.
Dairy productsSkimmed or semi skimmed milk.
Low fat, flavoured yoghurt, fromage frais.
Low fat cheese, shape, edam, brie, gouda, camembert, cottage cheese.
Full fat milk yoghurt or cheese, cream cheese or yoghurts containing fruit/nuts.
Blue cheese, condensed/ evaporated milk full fat ice cream.
FatsLow fat spreads, outline St. Ivel gold etc. Use sparingly.Butter, margarine, lard, dripping, suet, vegetable oils.
ConfectioneryBoiled sweets, fruit gums, pastilles, mints, jams without skins or pips, honey, sugar, treacle, syrup, jelly.Chocolate, toffee, fudge, sweets containing fruit/nuts.
Lemon curd, jams with pips or peel, mincemeat, marzipan.
DrinksTea, coffee, fruit squash, fizzy drinks, oxo, Bovril, low fat hot chocolate and malted drinks, some alcohol.Full fat chocolate drinks, cocoa, cream-based liqueurs,
e.g. Baileys.
MiscellaneousSalt, pepper, herbs, spices, vinegar, ketchup, stock cubes.Soups, peanut butter, cream or oil based salad dressings.

 

Date published: 28 February 2024 Review due: 28 February 2027 PI number: BFT003366
 

Flexible sigmoidoscopy

Regular Off Off

Important information

Please read all of this leaflet or you may miss important information about your test. If you do not follow the instructions we may need to cancel your test on the day.

What is flexible sigmoidoscopy?

A flexible sigmoidoscopy looks at the lower part of your large bowel (colon). Many patients choose to have Entonox (gas and air) during the procedure or take nothing at all. Some may prefer to have a light sedative.

How long will the sigmoidoscopy procedure take?

It takes around 10 to 20 minutes. In some cases this may be longer, but this does not mean anything is wrong. You should expect to be in the department 2 to 4 hours. Unfortunately, it may not always be possible to run on time. The staff will try to keep you informed.

Why do I need to have a sigmoidoscopy?

To help your doctor find the cause of your symptoms by looking directly at the lining of the colon. There are many reasons for this investigation including bleeding from the bottom, abdominal (tummy) pain, to look further at findings from another scan or X-ray, or surveillance of an existing condition.
During this test the endoscopist may take a biopsy (small sample of tissue) for testing, or remove polyps if appropriate. The tissue is removed through the endoscope using tiny forceps and does not hurt.

What are the benefits of this procedure?

To help diagnose and/or treat your condition. It may also help your doctor decide if any further investigations are required.

What if I do not have the sigmoidoscopy or change my mind?

It may be difficult to diagnose your condition or offer suitable treatment. You may find it helpful to discuss the test with your GP or referring doctor. If you decide not to go ahead, please let us know.

Can I seek a second opinion?

Yes, please seek advice from your GP or referring consultant.

Is there an alternative to a sigmoidoscopy?

A CT colonogram is an alternative to a sigmoidoscopy but samples cannot be taken during this. So if an abnormality is found, you may need an endoscopy after that.

What are the risks?

Bleeding: may occur at the site of biopsy or polyp removal (risk of less than 1 in 1000 examinations where this is performed). This usually isn’t too serious and bleeding may stop on its own. If it does not, it can be controlled by cauterization or injection treatment.

Perforation: (or tear in the bowel lining) the risk is approximately 1 for every 15,000. 

Reaction to medication: if you choose to have sedation, this may cause a problem with breathing, heart rate, or blood pressure. You will be monitored during the procedure to look out for this. Medication to reverse the sedation is available and we will support you as needed.

Missed diagnoses: there is a very small risk that the colonoscopy misses an abnormality due to small folds in the lining of the digestive tract. In these areas the views may be less clear.

Pain: most people can cope well with this procedure. It is common to experience discomfort for a short time, however, a small number of patients may have some pain.

Failure to complete the procedure: your comfort and safety are our priority, we will stop at any time if we cannot ensure this, or if there is a problem with equipment (this is rarer).

What preparation is required for my sigmoidoscopy?

The left side of the bowel needs to be empty so we can see it clearly. You will be given one of the following:

  • bowel preparation for you to take the day before the test
  • an enema for you to do yourself at home, 2 hours before your appointment

Sometimes the enema is done on the unit by the endoscopy nurses. We will give you detailed instructions. 

You may have been offered a pre-assessment telephone call to cover any questions you may have, if not please contact the helpline on: 0117 414 5077.

If you choose to have sedation, please make sure a responsible adult is available to collect you from the department and stay with you for at least 6 hours. Make sure you bring their contact details so we can let them know you are ready to be collected.

What about my medication?

You should take all your usual medication at the normal times with small sips of water unless you have been advised not to. Some medications need to be stopped or adjusted 1 to 2 weeks before your appointment.

Please notify the department as soon as possible if you:

  • have diabetes
  • take medication to thin your blood/prevent clotting like warfarin, apixaban, rivaroxaban, dabigatran, edoxaban, clopidogrel
  • take long term steroids
  • take iron tablets
  • take weight loss injections

Why have I been asked if I have a pacemaker/internal cardiac defibrillator?

Implanted permanent pacemakers or cardiac defibrillators can be affected by electrical interference which may happen during sigmoidoscopy. We can take precautions as long as you tell us before the procedure. Please notify the department if you have one.

Do I need to bring anything with me?

A list of your medications and any you may need to take while you are in the department, such as insulin, inhalers, or GTN spray.

A dressing gown and slippers, if you have them. You are advised not to bring valuables with you. Your belongings will stay with you throughout your stay.

What happens when I arrive?

Please speak to the receptionist. They will check your details and may ask you to complete a form with details of your medical history, and contact details of your next of kin and the person collecting you.

We ask your family and friends not to accompany you beyond this point. The department can be very busy and space is limited. We will tell them the approximate time that you will be ready. The recovery staff will call them with a time they can collect you.

The nurse will take you to an admission room to complete the paperwork, check your blood pressure, pulse, and oxygen levels to make sure you are well enough to have the procedure. If you have diabetes the nurse may also test your blood glucose level.

If you decide to have sedation, a cannula (flexible needle) will be inserted into a vein in the back of your hand or arm so that the intravenous sedation can be given. 

The nurse will discuss the risks and benefits of having the procedure to make sure you understand what the procedure involves. You will be asked to sign the consent form. You will be able to ask questions at this point.

Will I have sedation?

The sigmoidoscopy can be slightly uncomfortable but hopefully not painful. Many patients do not require sedation ban choose to have Entonox (gas and air) instead. This leaves the body after 30 minutes so you can leave the unit shortly after the procedure alone and carry on as normal. 

If you choose to have sedation, a cannula will be inserted in a vein in the back of your hand or arm. The sedation will make you drowsy but not unconscious. You will still hear what is being said to you. It is not a general anaesthetic. You will need to arrange for someone to collect you from the unit and stay with you for at least 6 hours. 

Your reaction times will be slower and your judgement impaired. You will not be able to drive, operate heavy machinery, sign any legally binding documents, or look after small children or vulnerable adults for 24 hours.

Can my relative/friend stay with me?

There is limited space within the department so unfortunately this is not possible. We will advise them of an approximate time for you to be collected.

Will I be in a mixed ward?

There are separate male/female waiting and recovery areas.

Who will be in the procedure room with me?

  • A nurse who will monitor and support you.
  • The endoscopist who will do the procedure.
  • Another nurse who will assist the endoscopist.

The procedure will be done by a consultant or a non-medical/ clinical endoscopist. In some cases, an endoscopist who is doing further training (a qualified professional) may also be there. They will be learning to perform endoscopy under direct, expert supervision.

If you would prefer not to have your sigmoidoscopy done by someone training, you can tell us before coming into the procedure room. 

Student nurses may also be there and be supervised by the training nursing staff.

What can I expect during the procedure?

When you enter the room, you will be introduced to the team. A checklist will be completed and you will be asked to confirm your details. This is standard procedure to ensure your safety.

You will be made comfortable on a trolley and any monitoring equipment attached. The nurse looking after you will be at your head throughout.

If you are having sedation this will be given through the cannula in the back of your hand or arm. Once you are relaxed the procedure will begin. The endoscopist will do a rectal examination before passing the endoscope into your bottom.

The endoscopist will inflate the bowel with air or water. This may be uncomfortable but it will pass.

What happens after the procedure?

You will be taken into the recovery area. If you have sedation you will be monitored. When you have recovered the staff will contact your relative/friend to tell them when you will be ready to go home. You will be given written discharge advice and cannula removed if you’ve had sedation. 

If you have had Entonox, once the effects have worn off you will be allowed to leave the unit on your own. 

In both cases you will be offered refreshments.

When do I find out the results?

Before you leave the department the results of will be explained to you together with any further tests that may be required.

Biopsies usually take at least 4 weeks to be processed, sometimes longer. You will be told the results by letter or at an outpatient appointment.

How will I feel after the sigmoidoscopy?

You may feel bloated due to air still in your bowel but this should soon settle. If you have had biopsies or polyps removed a small amount of blood may be present when you go to the toilet (poo).

What should I do when I get home?

If you have had Entonox you can return to your normal day as soon as you feel able. 

If you have had sedation, rest quietly for the rest of the day. You will be able to return to normal activities after 24 hours. 
You will be given detailed discharge advice before you leave the unit.

What if I feel unwell or have any concerns after I have been discharged?

If you have any of the following please contact your GP, NHS 111, or go to the Emergency Department and take your results with you:

  • a fever
  • passing a lot of blood from your bottom or black stools (poo)
  • severe abdominal pain
  • severe bloating or vomiting

A copy of your results is sent to your GP. You will also be given a copy in case you need to seek medical advice before your GP receives their copy.

If you have any concerns about your test please contact the  helpline. Leave your name, number and a short message: 0117 414 5077.

Date published: 18 March 2026 Review due: 31 March 2029 PI number: BFT002232

Colonoscopy

Regular Off Off

Important information

Please read all of this leaflet or you may miss important information about your test. If you do not follow the instructions we may need to cancel your test on the day.

What is a colonoscopy?

A colonoscopy looks inside the large bowel (colon), the last part of the digestive system, with an endoscope. It is inserted into your bottom and moved around the whole of the large bowel by the endoscopist.

The procedure usually takes 20 to 30 minutes. You should expect to be in the department 2 to 4 hours. Unfortunately, it may not always be possible to run on time. The staff will try to keep you informed.

Why do I need a colonoscopy?

Your doctor has referred you to investigate your symptoms, such as a change in bowel habit (going to the toilet), bleeding, or anaemia. It may be a review of a pre-existing condition such as colitis or surveillance for polyps. It may help us find a cause for your symptoms and help to plan further treatment.

What else may be done during the procedure?

During some procedures we may take small biopsies (samples or remove polyps. Occasionally you may need to return for further treatment. You will be advised on the day. 

What if I do not have the colonoscopy or change my mind?

It may be difficult to diagnose your condition or offer suitable treatment. You may find it helpful to discuss the test with your GP or referring doctor. If you decide not to go ahead, please let us know.

Can I seek a second opinion?

Yes, please seek advice from your GP or referring consultant.

Is there an alternative to colonoscopy?

A CT colonoscopy may show a cause for your symptoms however during a colonoscopy we are can also take biopsies and remove polyps.

What are the risks of a having a colonoscopy?

Complications are rare but it is important you are aware of them before the test.

Bleeding: may occur at the site of biopsy or polyp removal (risk of less than 1 in 1000 examinations where this is performed). This usually isn’t too serious and bleeding may stop on its own.  If it does not it could be controlled by cauterization or injection treatment. 

Perforation: (or tear in the bowel lining) the risk is around 1 in 10,000. 

Reaction to medication: if you choose to have sedation, this may cause a problem with breathing, heart rate, or blood pressure. You will be monitored during the procedure to look out for this. Medication to reverse the sedation is available and we will support you as needed.

Missed diagnoses: there is a very small risk that the colonoscopy misses an abnormality due to small folds in the lining of the digestive tract. In these areas the views may be less clear.

Pain: most people can cope well with this procedure. It is common to experience discomfort for a short time, however, a small number of patients may have some pain.

Failure to complete the procedure: your comfort and safety are our priority, we will stop at any time if we cannot ensure his, or if there is a problem with equipment (this is rarer).

How do I prepare for the colonoscopy?

To allow clear views the colon must be clear and empty of waste material (poo). If not, the test may to be postponed or repeated.

The bowel preparation that has been prescribed works as a powerful laxative to clear your bowel. Please read the instructions carefully, follow any dietary instructions, and increase your intake of clear fluids (like water).

What about my medication?

You should take all your usual medication at the normal times with small sips of water unless you have been advised not to. Some medications need to be stopped or adjusted 1-2 weeks before your appointment. 

Please notify the department as soon as possible if you:

  • have diabetes
  • take medication to thin your blood/prevent clotting like warfarin, apixaban, rivaroxaban, dabigatran, edoxaban, clopidogrel
  • take long term steroids
  • take iron tablets
  • take weight loss injections

Why have I been asked if I have a pacemaker/internal cardiac defibrillator?

Implanted permanent pacemakers or cardiac defibrillators can be affected by electrical interference which may happen during colonoscopy. We can take precautions as long as you tell us before the procedure. Please notify the department if you have one.

Do I need to bring anything with me?

  • A list of your medications and any you may need to take while you are in the department, such as insulin, inhalers, or GTN spray.
  • A dressing gown and slippers, if you have them. You are advised not to bring valuables with you. Your belongings will stay with you throughout your stay.

What happens when I arrive on the Endoscopy unit?

Please speak to the receptionist. They will check your details and may ask you to complete a form with details of your medical history, and contact details of your next of kin and the person collecting you.

The admitting nurse will take you into a private room to ask questions about your general health, allergies, the results of the preparation you have taken. They will also measure your blood pressure, pulse, breathing rate, and oxygen levels. If you are diabetic your blood sugar will be measured by a fingerpick test, and if on warfarin your INR will be checked.

You will be asked to sign the consent form  at this time either by the nurse or the endoscopist. If you have any questions or concerns, please let tell the nurse be aware. 

You may be able to have a companion/carer with you at this time, but they will not be able to come with you into the procedure room.

Following this you will be asked to change into a gown and wait in a separate waiting area until the procedure room nurse comes to collect you. If you decide to have sedation, a cannula (flexible needle) will be inserted into a vein to allow intravenous sedation to be given. 

This test is usually done with either Entonox - a gas you breathe in. Or you can have a sedative injection (midazolam) and an opiate painkiller injection (fentanyl). This is not a general anaesthetic, you will not be completely asleep, and you will be aware of your surroundings.

Sedation

If you decide to have sedation, a cannula (flexible needle) will be inserted into a vein to allow intravenous sedation to be given. 

You will need a responsible adult to come to the unit to collect you, take you home, and care for you for at least 6 hours. For 24 hours after having sedation you cannot drive, operate machinery, drink alcohol, look after small children or vulnerable adults, or sign any legally binding documents. If you have not made these arrangements, we will not be able to offer sedation.

Entonox is a mixture of nitrous oxide and oxygen inhaled through a mouthpiece. It is an odourless, colourless gas which provides short term pain relief. If works quickly and wears off quickly. You can drive 30 minutes after having it.

If you have recently had any of the following Entonox may not be suitable: eye or ear surgery, a recent head, recent scuba diving activity, chronic breathing conditions such as emphysema or chronic obstructive pulmonary disease (COPD).

Who will be in the procedure room with me?

  • A nurse who will monitor and support you.
  • The endoscopist who will do the procedure.
  • Another nurse who will assist the endoscopist.

The procedure will be done by a consultant or a non-medical/ clinical endoscopist. In some cases, another endoscopist who is doing further training (a qualified professional) may also be there. They will be learning to do colonoscopy under direct, expert supervision.

If you would prefer not to have your colonoscopy done by someone training, please let us know.

Student nurses may also be there and be supervised by the training nursing staff.

What can I expect during the colonoscopy?

  • Once in the procedure room you will be introduced to the team and they will ask you some questions. The Endoscopist will have a short conversation with you. 
  • You will lie on your left side on the trolley and be given the sedation or Entonox.
  • A short internal rectal examination is done before inserting the scope.
  • You will be monitored and cared for by your nurse throughout the procedure.
  • Once the procedure is complete you are taken, on the trolley, into the recovery area. You will continue to be monitored until you feel able to get up and dressed. Refreshments are available. 
  • The person collecting you will be contacted. 
  • You will be given discharge advice and paperwork, and details of any further tests needed. 
  • We will give you contact numbers in case you have issues once you go home.

Will I be in a mixed ward?

There are separate male/female waiting and recovery areas.

What should I do when I get home?

If you have had sedation please remember, you must not drink alcohol, drive, operate machinery, care for vulnerable adults or small children, or signing any legally binding documents.

You can eat and drink normally.

What if I feel unwell or have any concerns after I have been discharged?

If you have any of the following please contact your GP, NHS 111, or go to the Emergency Department and take your results with you:

  • a fever
  • passing a lot of blood from your bottom or black stools (poo)
  • severe abdominal pain
  • severe bloating or vomiting

A copy of your results is sent to your GP. You will also be given a copy in case you need to seek medical advice before your GP receives their copy.

If you have any communication or mobility difficulties, or any concerns about your test please contact the Endoscopy Helpline. Leave your name, number and a short message: 0117 414 5077.

Date published: 5 March 2026 Review due: 31 March 2029 PI number: BFT002231
 

Rheumatology Current Research

Regular Off Off

Rheumatology research taking place at North Bristol NHS Trust

Please speak to the person treating you to see if there is a research study that may be able to help you.

Current Studies:

BSRBR-RA

The BSRBR-RA study tracks the progress of people with rheumatoid arthritis (RA) who have been prescribed biologic (including biosimilar) and other targeted therapies in the UK, to monitor the long-term safety of these drugs.

Project Details
Principal Investigator: Dr Paul Creamer
Planned End Date: 30/09/2028
Local Ref: 3512

BSRBR-PsA

The study evaluates the long-term course of PsA and,patients are followed up annually, comprising patient and treatment characteristics, clinical parameters,patient-defined benefit, quality of life and adverse events. In addition, patients starting a boDMARD, bsDMARD, or tsDMARD agent (either at recruitment or subsequently) will be followed up three and six months after the commencement of that therapy, with the follow-up schedule being ‘reset’ in the event of switching between therapies. Questionnaire follow-up is tied to patients’ anticipated clinical visit schedule, and clinical centres are contacted regarding any patients lost-to-follow- up. Safety issues, serious adverse events and supplementary information are collected by standardised forms.

A biobank is also being created as part of the study. Where local facilities allow, participants may be asked to donate tissue samples (blood and urine) which, alongside the extensive clinical phenotyping, will help facilitate biomarker evaluation and the identification of specific bio-molecular predictors of treatment response.

Project Details
Principal Investigator: Dr Paul Creamer
Planned End Date: 30/09/2024
Local Ref: 4721

MINIMISE

Systemic sclerosis or scleroderma is an autoimmune condition that causes thickening and hardening of the skin, but can also affect internal organs.

There are two major subsets of scleroderma: the limited cutaneous systemic sclerosis (lcSSc) that usually affects the skin of the face, neck, lower legs or lower arms, but can also lead to internal organ complications, and the diffuse cutaneous systemic sclerosis (dcSSc), that may affect blood circulation and internal organs, as well as the skin.

To date there is no drug that has been definitively proven to cure or modify the course of scleroderma. However, there is emerging evidence that immunosuppression and specifically mycophenolate mofetil (MMF) may be beneficial in lcSSc. The MINIMISE-Pilot trial would be an important first step to evaluate the risk and potential benefit to this disease group. MMF as the intervention of choice is both appropriate and timely, as it has been routinely used in the management of dcSSc.

The MINIMISE-Pilot trial aims to explore whether the immunosuppressive agent MMF at a target dose of 2g daily can slow down disease progression in patients with lcSSc compared to the current standard of care alone. This pilot trial will also provide critical information for the development of a future large trial that could potentially transform lcSSc patient management. This is an open label randomised prospective trial that will recruit 120 participants aged 18 or over across 13 sites in the UK. The trial will involve five (5) clinic visits which are expected to be carried out at the same time of the participants routine hospital appointment. In addition, they will receive four (4) routine telephone calls in between their clinic visits. Participants are expected to be followed up for a minimum of 48 weeks or a maximum of 96 weeks.

Project Details
Principal Investigator: Dr H Gunwardena
Planned End Date: TBC
Local Ref: 4766

UKIVAS

Primary systemic vasculitidies (PSV), encompassing Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated vasculitis and medium vessel vasculitis, are relatively uncommon diseases, but have a propensity for renal involvement and account for a significant number of patients with both acute and chronic kidney disease. The aetiology of PSV is unknown and current therapies are non-specific and associated with major side effects. Outcome data for such patients have comprised small cohort studies from single centres. Understanding the factors that influence disease outcome and the impact different therapies have outside of clinical trials can only be achieved using a larger number of patients, accrued from multiple different units.

We propose to establish the first pan-UK PSV dataset, which will collect regular returns regarding patient recruitment and outcome from all participating centres. This will facilitate investigation of disease associations, outcomes and demographic trends for the UK PSV population. We will test the hypothesis that disease incidence is increasing in Indo-Asians and why the outcome may be different among different ethnic groups, as well as investigating contemporary outcomes with modern immunosuppressive protocols. In addition, we will combine clinical phenotype with genetic studies. Specifically we will investigate genetic variation between ethnic groups by looking at variations in DNA sequences that can help to explain differences in disease susceptibility. These are investigated using many DNA specific markers, called single-nucleotide polymorphisms (SNPs) whose expression will be compared between patients from different ethnic groups.

Finally, we will be able to record the outcome of all patients treated with novel therapeutics, thus eliminating the significant reporting bias that exists. This will allow individual investigators to carry out particular projects mining the dataset.

Project Details
Principal Investigator: Dr Albert Power
Planned End Date: 28/02/2022
Local Ref: 3724

BILAG

The BILAG Biologics Prospective Cohort is a prospective observational cohort study of patients with SLE who are starting treatment with a biologic drug or a conventional, non-biologic therapy. The study aims to recruit 220 patients into the biologic treatment group and a further 220 patients into the conventional, non-biologic therapy cohort.

The aim of the BILAG BR is to ascertain whether using biologics in the routine treatment of SLE is associated with an increased risk of hospitalisation for infection, compared to SLE patients with similar disease activity receiving conventional therapies. The secondary purpose of the BILAG Biologics Prospective Cohort is to determine the long-term efficacy of biological therapies in the treatment of SLE.

This prospective cohort study will recruit an exposed cohort of patients with SLE treated with biological therapies and an unexposed cohort of patients with similar disease characteristics but exposed only to conventional non-biological therapies. Comprehensive data will be collected at baseline, from the clinic team and the patient, including data on disease diagnosis and activity, risk factors for infection and routine laboratory results. Follow-up data will be collected at 3, 6, 12, 24 and 36 months to include any changes in medications, adverse events, hospitalisations for infections, disease activity and quality of life along with biological samples for biomarker analysis.

Project Details
Principal Investigator: Dr Harsha Gunawardena
Planned End Date: 31/12/2022
Local Ref: 8251

Paused Studies:

MYOPROSP

Idiopathic Inflammatory Myopathies (IIM), also know as myositis, is a rare condition that causes inflammation of the muscles and can result in weakness, fatigue and disability. It can also affect other parts of the body including the skin, joints, heart, lungs and digestive tract. Treatment involves the suppression of inflammation using anti inflammatory medication before permanent damage results. However, the outcome for patients with myositis is not as good as it could be and needs to be improved. For this reason we are planning a research study to find better ways to diagnose, treat and improve the care of patients with myositis.

Patients wishing to take part will ideally attend for 4 study visits over the course of 12 months. If they continue to be seen at the hospital, they may also be asked to provide further blood samples and information on an annual basis for 5 years. At the initial visit they will be asked to sign a consent form, give a blood sample, undergo a clinical assessment and complete a number of questionnaires. Additionally (as part of their routine clinical care), they will be asked to undertake an MR scan of their muscle, a muscle biopsy, and be given the option of an MR contrast scan of their heart (these clinical results will be used as part of research findings. Follow up visits at 3, 6 and 12 months will involve further blood samples, clinical assessments and questionnaires. Additionally, they will be given the option of a second MR muscle scan, a repeat muscle biopsy and an MR contrast scan of their heart at the 6 month follow up visit.

It is hoped that the information gained from this study will help identify better ways to diagnose, treat and improve the care of patients with myositis.

Project Details
Principal Investigator: Dr Harsha Gunawardena
Planned End Date: 31/12/2020
Local Ref: 3793

Take Part in Research

Patient & Doctor viewing an x-ray

Become one of the thousands of people taking part in research every day within the NHS.

About Research & Development

NBT Researcher

Find out more about our research and how we're working to improve patient care.

Contact Research

Research & Development
North Bristol NHS Trust
Level 3, Learning & Research building
Southmead Hospital
Westbury-on-Trym
Bristol, BS10 5NB

Telephone: 0117 4149330
Email: research@nbt.nhs.uk

R&I Rheumatology.jpg

Multiple Sclerosis Current Research

Regular Off Off

Multiple Sclerosis research taking place at North Bristol NHS Trust

Please speak to the person treating you to see if there is a research study that may be able to help you.

Current Studies:

MS-STAT2

Multiple Sclerosis (MS) is a progressive neurological disorder of the brain and spinal cord. It affects approximately 120,000 people in the UK and 2.5 million people globally. Most people with MS experience two stages of the disease:

Early MS – Relapsing-Remitting MS (RRMS), which is partially reversible.

Late MS – Secondary Progressive MS (SPMS), which affects the majority of patients, usually after 10 to 15 years after diagnosis.

SPMS results from progressive neuronal degeneration that causes accumulating and irreversible disability affecting walking, balance, manual function, vision, cognition, pain control, bladder and bowel function. The pathological process driving the accrual of disability in SPMS is not known at present.

Immunomodulatory anti-inflammatory disease modifying therapies (DMTs) are increasingly effective in reducing relapse frequency in RRMS, however, they have been unsuccessful in slowing disease progression in SPMS. This is the overwhelming conclusion from an analysis of 18 phase 3 trials (n=8500), of which 70% of the population had SPMS, all performed in the last 25 years. There is no current disease modifying treatment (DMT) for SPMS.

In an earlier study (MS-STAT1), 140 people with SPMS were randomly assigned to receive either placebo or simvastatin for a period of two years. The investigators found that the rate of brain atrophy (loss of neurons - ‘brain shrinkage’), as measured by magnetic resonance imaging (MRI), was reduced in patients receiving simvastatin compared to those taking placebo.

Several other long term studies have also reported that there might be a relationship between the rate of brain atrophy and the degree of impairment.

The study is designed to test the effectiveness of repurposed simvastatin (80mg) in a phase 3 double blind, randomised, placebo controlled trial (1:1) in patients with secondary progressive MS (SPMS), to determine if the rate of disability progression can be slowed over a 3 year period.

Project Details
Chief Investigator: Dr Claire Rice
Planned End Date: TBC
Local Ref: 4104

A prospective, real world pharmacovigilance study in Multiple Sclerosis

This pragmatic, prospective observational cohort study is planned to run for 7 years to estimate the frequency of serious adverse events with real world DMT use in routine clinical practice in the UK. It is a non-interventional cohort study. The study will recruit people with MS on treatment from major MS care clinics across the country, as well as those starting, switching or potentially eligible for treatment, but who are not currently taking DMT. This study will provide – for the first time - an estimate of overall rates of serious adverse events associated with DMT (including multiple sclerosis relapses or opportunistic infections) in the UK population with MS. It will facilitate a way of exploring related questions regarding the relative benefits vs risks of treatment and the influence of prior treatments on adverse events.

Project Details
Principal Investigator: TBC
Planned End Date: TBC
Local Ref: 4635

Take Part in Research

Patient & Doctor viewing an x-ray

Become one of the thousands of people taking part in research every day within the NHS.

About Research & Development

NBT Researcher

Find out more about our research and how we're working to improve patient care.

Contact Research

Research & Development
North Bristol NHS Trust
Level 3, Learning & Research building
Southmead Hospital
Westbury-on-Trym
Bristol, BS10 5NB

Telephone: 0117 4149330
Email: research@nbt.nhs.uk

R&I MS.jpeg

Immunology Current Research

Regular Off Off

Immunology research taking place at North Bristol NHS Trust

Please speak to the person treating you to see if there is a research study that may be able to help you.

Current Studies:

Hereditary Angioedema (HAE) studies a disorder that results in recurrent attacks of severe swelling.
Please speak to the person treating you to see if you can take part in our current research studies listed below.

Oasis - IONIS CS7

A phase 3 double blind, placebo-controlled study to evaluate the efficacy and safety of prophylactic Donidalorsen in HAE. Patient recruitment is closed but current and new participants may enrol to an open-label extension study. Patients need to have at least 2 HAE attacks within the last 2 consecutive months to participate. There are also other inclusion /exclusion criteria and recruitment is subject to availability.

Project Details
Principal Investigator: 
Planned End Date: 31/12/24
Local Ref: 5248

Chapter-1 Pharvaris

Chapter-1 is a phase 2 double-blind, placebo-controlled, randomized, dose-ranging, parallel group study to evaluate the safety and efficacy of PHA-022121 administered orally for prophylaxis against angioedema attacks in patients with HAE. Patients need to have at least 3 HAE attacks within the last 3 consecutive months to participate. There are also other inclusion /exclusion criteria and taking part in the study is subject to availability.

Project Details
Principal Investigator: 
Planned End Date: 31/12/2023
Local Ref: 5046

Take Part in Research

Patient & Doctor viewing an x-ray

Become one of the thousands of people taking part in research every day within the NHS.

About Research & Development

NBT Researcher

Find out more about our research and how we're working to improve patient care.

Contact Research

Research & Development
North Bristol NHS Trust
Level 3, Learning & Research building
Southmead Hospital
Westbury-on-Trym
Bristol, BS10 5NB

Telephone: 0117 4149330
Email: research@nbt.nhs.uk

R&I Immunology.JPG

Genetic testing in inherited breast and ovarian cancer R208

Regular Off Off

This leaflet has been written for people who have a personal or family history of breast cancer that could have an inherited cause, and who are considering having a genetic test. It has been written for use with a Clinical Genetics appointment and may answer some of your questions.

Is breast and ovarian cancer inherited?

It is rare for breast and ovarian cancer to be inherited. However, breast cancer occurs in many women, with around one in every seven in the UK developing the disease during their lifetime. Ovarian cancer develops in around one in 50 women in their lifetime. In about 5 - 10% of these cases, a specific gene alteration plays a part. We currently test for 5 genes: BRCA1, BRCA2, PALB2, ATM and CHEK2 in the R208 test. If any of these genes are altered, that person has a substantially increased risk of developing certain types of cancer, depending on which gene is affected.

What are genes?

Our genes can be found in almost every cell in our body. They are the instructions that enable our bodies to grow and function correctly. BRCA1, BRCA2, PALB2, ATM and CHEK2 are tumour suppressor genes that help to protect us from developing cancer. An alteration can affect the function of the gene. This can increase the chance of developing, for example, breast, ovarian and prostate cancer, which is more likely to occur at a younger age.

How are these genes inherited?

All our genes come in pairs; we inherit one of each pair from our mother and the other from our father. Alterations in the genes in the R208 test are inherited in an ‘autosomal dominant’ manner. This means that the children (male or female) of a person with an alteration in one of these genes have a 1 in 2 (50%) chance of inheriting it. An alteration can be inherited from either parent.

If a person has not inherited an alteration, they cannot pass it on to their children.

Autosomal dominant inheritance - gene diagram showing how an altered gene can be passed on

Can genetic test results be uncertain?

Sometimes we find an alteration in a gene, but we are not sure of its significance. This is called a variant of uncertain significance (VUS). If we are uncertain whether the gene alteration found is the cause of the cancers in your family, we will not be able to offer a predictive genetic test to other family members. However, we may ask for extra samples from you or other family members to try to gather more information. Often these extra tests help to establish whether or not the VUS is the explanation for your family history of cancer.

What if a relative who has had cancer is not available for testing?

In some cases, where there is no affected family member available for testing we may:

  1. Offer testing to someone in the family who has not had a cancer. This may be offered if the family history gives a high enough chance that there is a gene alteration. (The relative without cancer must have a 10% chance of having a gene alteration). Testing someone who has not had cancer may make some results harder to interpret. For example, if no gene alteration is found we would not know whether there is a gene alteration that this relative has not inherited or there is another cause for the family history.
  2. It may be possible to test a tumour sample from a relative who has passed away. Testing tumour samples is more technically difficult than testing a blood sample. It is possible that this test will not work because of the way the tumour samples are stored.

Does everyone who has an alteration in one of these genes get breast cancer?

No. The chance of developing breast and other cancers associated with the genes is not 100%. We do not yet know why some people with an alteration develop cancer and some do not. Lifestyle or other genetic factors are likely to play a role. It is important to note that developing cancer is not the same as dying from cancer. Even if cancer develops, there is a chance that the disease can be cured if it is found and treated early.

What are the genes in the R208 test and the risks associated with them?

BRCA1:

Breast cancer

  • Female carriers - 60% to 80%
  • Male carriers - 1%
  • Members of the general population - 14% (female), 1% (male)

Ovarian cancer

  • Female carriers - 40% to 60%
  • Male carriers - men do not have ovaries
  • Members of the general population - 1% to 2% (female)

 Prostate cancer

  • Female carriers - women do not have a prostate gland
  • Male carriers - minimal increased risk
  • Members of the general population - 12%

Pancreatic cancer

  • Female carriers - up to 3%
  • Male carriers - up to 3%
  • Members of the general population - 1.8%


BRCA2:

Breast cancer

  • Female carriers - 60% to 80%
  • Male carriers - 6%
  • Members of the general population - 14% (female), 1% (male)

Ovarian cancer

  • Female carriers - 10% to 30%
  • Male carriers - men do not have ovaries
  • Members of the general population - 1% to 2% (female)

 Prostate cancer

  • Female carriers - women do not have prostate gland
  • Male carriers - 25% (often more aggressive in younger men)
  • Members of the general population - 12%

Pancreatic cancer

  • Female carriers - 2% to 7%
  • Male carriers - 2% to 7%
  • Members of the general population - 1.8%

Remember, 10 per cent means one person in every 10 will develop this cancer in their lifetime.

For women who have already been affected with breast cancer, we know there can be an increased chance of developing a completely new cancer. This is different to a cancer which recurs or spreads from the first (original) cancer. Please discuss this with your clinician.
 

PALB2:

Breast cancer

  • Female carriers - 13% to 21% by age 50, 44-63% by age 80
  • Male carriers - less than 1% by age 50, around 1% by age 80
  • Members of the general population - 14% (female), 1% (male)

Ovarian cancer

  • Female carriers - less than 1% by age 50, around 5% by age 80
  • Male carriers - men do not have ovaries
  • Members of the general population - 1% to 2% (female)

 Prostate cancer

  • Female carriers - women do not have prostate gland
  • Male carriers - minimal increased risk
  • Members of the general population - 12%

Pancreatic cancer

  • Female carriers - less than 1% by age 50, 2-3% by age 80
  • Male carriers - less than 1% by age 50, 2-3% by age 80
  • Members of the general population - 1.8%

Family history is taken into account to calculate an individualised risk assessment
 

ATM:

Breast cancer

  • Female carriers - 17% to 30% (Except c.7271T>G which is over 30%)
  • Male carriers - minimal increased risk
  • Members of the general population - 14% (female), 1% (male)

CHEK2:

Breast cancer

  • Female carriers - around 25%
  • Male carriers - minimal increased risk
  • Members of the general population - 14% (female), 1% (male)

What are the implications of the R208 test?

This testing can sometimes tell you that your chance of developing cancer is increased, but we cannot tell you for certain when, or even if, you will develop cancer. 

If an alteration is found in any of the genes in the panel, there is an increased chance of developing cancer. Some people may worry that genetic testing will affect insurance prospects (for example, health, life, or disability insurance). Currently, the insurance industry cannot ask about genetic testing for most policies. This position may change in the future. 

Some people feel a range of emotions when they are told that they have a gene alteration which increases their chance of cancer. They may feel angry, shocked, anxious or guilty about the possibility of passing the gene alteration on to their children. Some people may also feel guilty if they do not have the gene alteration when other close relatives do.

Genetic testing in a family can affect other family members, who may need to be told that they too are at an increased risk of developing cancer and may be eligible for genetic testing and/or screening. Different family members may have different reactions to this information, and genetic testing may therefore affect relationships within families. Your clinician will provide you with a letter that you can pass onto relatives to help them to access genetic testing.

Can having a BRCA1 or 2 gene alteration affect cancer treatment?

There are new drugs available called PARP inhibitors (Olaparib and Niraparib) which have been shown to improve survival in individuals diagnosed with breast or ovarian cancer who have a BRCA1 or 2 gene alteration. PARP inhibitors are not currently used for carriers of PALB2, ATM or CHEK2.

What screening is available for women with alterations identified through the R208 test?

MRI (magnetic resonance imaging)

Breast MRI is the most effective form of breast screening for younger women. Breast MRI is offered to women with a BRCA1, BRCA2, PALB2 or ATM c.7271T>G gene alteration every year from 30 until 49 years of age. Women who have a 50% or 1 in 2 chance of having these specific gene alterations are also eligible for this screening. 

Mammography

This form of screening has not been proven to be effective in women under the age of 40. It has been shown to be beneficial over the age of 40, especially alongside breast MRI. 

Women with a BRCA1, BRCA2, PALB2 or ATM c.7271T>G gene alteration are offered annual mammograms from 40 until 69 years of age. Women who have a 50% or 1 in 2 chance of having these specific gene alterations are also eligible for this screening. 

Women with a CHEK2 or any other ATM gene alteration are offered annual mammograms from 40 until 49 years of age. They are then enrolled into the NHS breast screening programme to have mammograms every 3 years from 50-69 years of age.

From 70 years of age, women can request to have a mammogram every three years by contacting their local breast unit or GP.

Is there any screening for ovarian cancer?

Some recent evidence suggests that ovarian cancer may help to detect ovarian cancer at an earlier stage. However, there is not enough evidence yet that this screening saves lives. Therefore, it is not currently offered as part of NHS treatment.

Is there any other recommended screening?

If you have a family history of pancreatic cancer, you could talk to your clinician about whether or not pancreatic screening is an option for you.

Having an alteration in one of the genes on the R208 test may be associated with increased risks of developing other types of cancer. The risks of these are likely to be small and there is no additional screening recommended currently.

Risk reducing breast surgery (risk reducing bilateral mastectomy)

This is the surgical removal of healthy breasts to prevent a cancer developing. This has been shown to reduce the chance of developing breast cancer by 90-99%. It does not remove all the risk, as the surgery cannot remove every breast cell. It is a major operation that can have serious complications, so it requires careful consideration. This is only available to women whose lifetime risk of developing breast cancer exceeds 30%.

Risk reducing removal of the ovaries and fallopian tubes (risk reducing bilateral salpingo-oophorectomy)

This is the surgical removal of healthy ovaries and fallopian tubes to prevent cancer developing, which reduces the risk of ovarian cancer by 95%. There is still a small chance of an ovarian-like cancer developing in the surrounding tissue that is left. This is estimated to be between 2 to 5% in a lifetime. In some circumstances, this may also help to reduce the risk of breast cancer if carried out before the natural menopause. Having ovaries removed will start an immediate menopause. Therefore it may be appropriate to have some form of hormone replacement therapy (HRT) until 50 years of age. HRT may not be recommended for women who have had hormone receptor positive breast cancer.

Is there any medication which can reduce the risk of developing breast cancer?

Taking certain medications for five years has been shown to reduce the risk of breast cancer in women at increased risk. Tamoxifen can be offered prior to the menopause, or Raloxifene and Anastrazole after the menopause. These drugs are associated with side effects. Please ask your clinician if interested, and/or see our separate chemoprevention leaflet.

Symptom awareness

We also recommend breast and ovarian cancer awareness for women, and breast and prostate awareness for men. Your clinician will provide you with the relevant booklets from Macmillan with more information about this. Alternatively, there is more information online at www.macmillan.org.uk. These booklets also include information about lifestyle factors which can help to reduce cancer risk in general.

What screening is available for men with alterations identified through the R208 test?

There is currently no national screening programme for prostate cancer in the UK. This is because it has not been proven that the benefits outweigh the risks. Instead of a national screening programme, there is an informed choice programme called prostate cancer risk management. The PSA test is a blood test to help detect prostate cancer. It measures the level of prostate-specific antigen (PSA) in your blood. This is available to healthy men aged 50 or over, who ask their GP about PSA testing. It aims to give men good information about the pros and cons of the PSA test. 

BRCA2

Given the increased risk, men with a BRCA2 alteration can be referred to a Urologist to discuss the option of prostate screening in more detail. Currently prostate screening involves measuring PSA levels, but may also involve an initial MRI.

BRCA1, PALB2, ATM and CHEK2

The risk of developing prostate cancer is not greatly increased. Therefore, prostate screening is not currently offered to men with these gene alterations, although they could discuss with their GP about prostate cancer risk management.

Are there any options for people with an altered gene who are planning a family?

Many people with an altered gene opt to have children in the usual way. Alternatively, women or men with a BRCA1, BRCA2 or PALB2 gene alteration may have the option of having Pre-implantation Genetic testing (PGT) involves undergoing the fertility treatment in-vitro fertilisation (IVF). PGT has the extra step of genetic testing of the embryos (fertilised eggs). The aim is to only put embryos into the womb which have not inherited the gene alteration. The Genetic Counsellor or Clinical Genetics Doctor can discuss this in more detail with individuals who are keen to consider this option. Testing in pregnancy is theoretically possible, but not often considered for conditions that affect people as adults.

Is there an alternative to genetic testing?

You may decide not to have genetic testing. Whether or not you are tested, you should talk to your clinician about screening options for you and your relatives.

I’ve heard of research studies involving people with a family history of cancer. How can I find out more?

There may be research studies that you are eligible to take part in if you wish. It is important to remember that research studies may not benefit you directly but may help future generations.

How to contact us:

Gates 24A
Brunel building
Southmead Hospital
Westbury-on-trym
Bristol
BS10 5NB

© North Bristol NHS Trust. This edition published March 2023. Review due March 2026. NBT003389

Nerve root blocks and lumbar sympathetic blocks

Regular Off Off

Your doctor has requested that you have a nerve root block either to help diagnose the cause of your pain or try to relieve it. 

We hope that the following information will answer some of the questions you may have about this procedure.

What is a nerve root?

Nerve roots exit the spinal cord and divide into nerves that travel to your arms and legs. These nerve roots can become inflamed due to pressure from nearby bone spurs or intervertebral discs. Inflammation of nerve roots may cause pain in the back, neck/arms and/or the legs. A nerve root block provides important information for your doctor and may also provide you with some relief from pain.

Why do I need to have a nerve root block done?

The procedure is designed to prove which nerve is causing your pain by placing temporary numbing medicine over the nerve root of concern. If your pain improves after the injection then that nerve is the most likely cause of your pain. If your pain remains unchanged, then that nerve is probably not the cause of your pain.

What is injected around the nerve root?

The injection is a combination of local anaesthetic (a numbing agent) and steroid (an anti-inflammatory agent). The local anaesthetic works immediately and the steroid begins to work within 2-3 days.

How do I prepare for a nerve root block?

There is no preparation for this procedure; you can continue to eat and drink as normal.

If you are diabetic please inform the doctor before the examination as there is a possibility that your sugar levels will vary after the injection. It is important that you continue to monitor your levels carefully for several days and consult your GP if necessary.

What will happen during the procedure?

You will be shown to a cubicle where you will be asked to undress in private and put on a gown. If you need assistance we can provide it.

You will then be shown into the X-ray room for the examination and introduced to the staff performing the procedure. You will be cared for by a small team including a radiologist/pain physician, radiographer and nurses.

Before the examination begins the radiologist/pain physician will explain what they are going to do and then ask you to sign a consent form.

You will then be asked to lie on your front or back on the X-ray couch. The skin will be cleaned and the doctor will inject a small amount of local anaesthetic under the skin. This stings for a few seconds and the area then goes numb.

The radiologist/pain physician will then direct a very small needle just next to the nerve root using the X-ray machine to guide the needle. Sometimes the needle can touch the nerve itself in which case you may feel a sharp pain going down your leg. This will only last for a second or two. A special dye called contrast medium is then injected around the nerve root. This shows up on the X-ray machine to confirm the needle is in the correct position. When the pain consultant/radiologist is satisfied with the needle position, the pain killing medicine will be injected along the nerve root.

How long will it take?

You will be awake throughout the procedure, which lasts about 15 – 30 minutes.

Will it hurt?

You may feel a little pressure or discomfort, which may travel down the arm/leg, during the injection of the pain killing medicine. This will last for only a few seconds.

Afterwards your leg may feel numb or weak for up to 24 hours. You will be asked to wait for 30 to 60 minutes before going home and you should not drive for the rest of the day. You will need to arrange for someone to take you home. Some people find that their pain feels worse for 2-3 days after the procedure. This is because the steroid can sometimes irritate the nerve. Do not worry if this happens, as it will settle down by itself. 

If your leg becomes numb you may need to stay in hospital overnight.

Are there any risks associated with a nerve root block?

Generally it is a very safe procedure. Potential complications are uncommon and include:

  • Bleeding or haematoma (a bruise under the skin) – this should settle down by itself.
  • Infection – contact your GP if you experience any redness or tenderness at the injection site.
  • An allergic reaction to the contrast dye – please inform the doctor doing the nerve root block if you have any allergies.

Please inform your pain consultant if you take any blood thinning medication such as Warfarin, Clopidogrel, Rivaroxaban, Dipyridamole, Dabigatran. It is very important you contact us PRIOR to attending your procedure. Please note this list is not exhaustive.

Please also inform the pain consultant if you are a diabetic as there is a possibility the steroid may affect your blood sugar levels. It is therefore important you monitor your levels carefully for several days after the procedure and consult your GP if necessary.

The procedure uses X-rays to confirm that the needle is in the correct place. The amount of X-rays used is very small however female patients who are or who may be pregnant should inform the department before attending for 
their appointment.

Finally

We hope this information is helpful. If you have any questions either before, during or after the procedure the staff at the Pain Clinic or X ray department will be happy to answer them.

The telephone number of the X-ray department can be found on your appointment letter.

Additional Information for Pain Clinic patients having a lumbar sympathetic block.

What is Lumbar Sympathetic Block?

There are nerves running either side of the lumbar spine, that control blood supply to the muscles and  skin of the legs. Injecting these nerves with local anaesthetic and/or a drug, may help your pain and improve your mobility.

What will happen during the procedure?

The procedure is done in the same way as a Nerve Root Block, except a dye is not injected.

What will happen after the procedure?

You will be asked to stay for approximately 30-60 minutes in the recovery area/Medirooms.

Your blood pressure, pulse and temperature will be monitored and you may need to lie down for a little while.

You should not drive after this procedure. You will need an escort to take you home and stay with you overnight. 

If your leg becomes numb, you may have to stay in hospital overnight.

You can restart your normal activities the following day.

References

Botwin et al (2002) Fluoroscopically guided lumbar transforaminal epidural steroid injections in degenerative lumbar stenosis: an outcome study. American Journal of Physical Medicine and Rehabilitation 81(12) 898-905

Vad et al (2002) Transforaminal epidural steroid injections in lumbosacral radiculopathy: A prospective randomised study. Spine 27(1) 11-15

Waldman S (2004) Atlas of Interventional Pain. 2nd Edition. Saunders. Philadelphia

NHS Constitution. Information on your rights and responsibilities. Available at www.nhs.uk/aboutnhs/constitution

How to contact us:

Pain Clinic
Gloucester House
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

0117 4147361

PainClinicClinical@nbt.nhs.uk

If you or the individual you are caring for need support reading this leaflet please ask a member of staff for advice.

Medial branch blocks

Regular Off Off

What is a medial branch block? 

This procedure is for diagnosis only and is not for permanent pain relief. Your pain is likely to return a few hours after the procedure. 

Facet joints are found between each of the spinal bones and allow the spine to move. The medial branches are nerves that carry information, including pain, from the facet joints to the brain. 

Sometimes back pain arises from these joints. A medial branch block uses local anaesthetic to numb these small nerves. If the pain is coming from the joints the pain may be reduced for some hours following these injections. 

Following this procedure we can determine whether the facet joints are the cause of your pain. Depending on the results, your consultant may offer a longer-lasting treatment that could be done after your follow up call or visit. 

How do I prepare for the medial branch blocks? 

There is no preparation for this procedure. You can eat and drink on the day as normal. You are advised not to drive for that day.

Please tell us before attending for the procedure if you take any blood thinning medication such as: warfarin, clopidogrel, rivaroxaban, dipyridamole, dabigatran. Please note this list is not exhaustive.

What will happen during the procedure? 

You will be shown to a cubicle in one of the medi-rooms where you may be asked to change in to a gown, if you need assistance please ask. The nurse will ask you some questions and record your observations.

You will be taken to the room where your procedure will be performed under X-ray. The doctor will explain the procedure and ask you to sign a consent form. You will be asked to lie on your front on the X-ray trolley. The skin around the site of the injection will be cleaned and you will be given a local anaesthetic. The number of injections will depend on your symptoms. 

Will it hurt?

 You may have some discomfort during the procedure. If you feel uncomfortable, let the doctor or nurse know and they will try to make you more comfortable. 

How long will it take? 

You will be awake throughout the procedure, which lasts about 15 – 30 minutes. What happens after my injections? After your injections you will be taken back to the medi-room, where a nurse will check and record your observations. You will be able to have something to eat and drink and then you can go home. You will have a small dressing on the area that has been treated that you can take off later that day.

How will I feel after the injections? 

Remember that medial branch blocks are not a treatment. They are done to help us diagnose the source of your pain. Immediately after the injections you may feel less pain but it will probably return after a few hours. 

Are there any risks or side effects? 

Generally it is a very safe procedure but as with any treatment there are risks or side effects. 

The doctor will discuss these more fully with you before you sign your consent form. The procedure is performed under X-ray to confirm the needle is in the correct place. 

Female patients who are or may be pregnant should inform the department before attending their appointment. 

What should I look out for when I go home? 

Anyone having an injection is at risk of infection. This is very rare but some of the signs of infection include: 

  • Redness, swelling, and heat around the injection site.
  • Increased temperature.
  • Generally feeling unwell.

Increase in pain

  • It is not unusual for your pain to worsen temporarily, but it can also remain the same.
  • Take your painkillers as normal.
  • Apply heat/cold to the affected area.
  • Try to keep active.

Who should I contact if I have any concerns? 

If you have any concerns please contact the Pain Clinic on: 

0117 4147380 

Monday- Friday 9am - 5pm 

Please contact your GP at any other time.

How to contact us:

Pain Clinic
Gloucester House
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

0117 4147361

PainClinicClinical@nbt.nhs.uk

© North Bristol NHS Trust. This edition published February 2024. Review due February 2027. NBT002592.

Spinal cord stimulator for pain relief

Regular Off Off

Spinal cord stimulation may have been offered to you as a treatment for your pain. This page tells you about spinal cord stimulation, the procedures and the after care.

Spinal cord stimulation

Spinal cord stimulation works by sending small electrical impulses to your spinal cord. An electrode is placed over the spinal cord and is powered by a battery which is implanted in the buttock or abdomen. Stimulation helps to block the pain signals travelling to the brain. It may feel like a tingling sensation which may help reduce your pain. Or you may not feel any tingling sensation. The amount your pain that may be reduced varies from person to person.

Stage one: trial stimulation

To establish if spinal cord stimulation may give you pain relief you will have a trial period of stimulation.

This involves an electrode being inserted under local anaesthetic over your spinal cord. The procedure is performed with you awake as we need you to be able to tell us in which areas you are experiencing the stimulation and whether or not they are in the area of your pain.

You will be required to lie face down. This may be from one to two hours. You will have a needle placed in the back of your hand through which you will be given a dose of antibiotics. A needle will be placed in your back and a fine wire is threaded up through this needle. You may experience pain in your back/neck or leg/arm during the passage of this wire. When this has reached a suitable position as judged by the image on an X-ray screen, you may be tested with a trial stimulation.

We will keep you as comfortable as possible. The procedure can feel uncomfortable but in rare circumstances it can be quite painful when the electrode is introduced and may leave you uncomfortable for a time after the procedure.

When a suitable position for the electrode has been achieved, the wire is then brought out through the skin and attached to your back with a stitch.

When we have moved you onto a trolley we will attach the lead to a temporary battery and give you a remote control type device to trial the stimulation. We like you to have a trial of about 5-10 days. This is best done at home where you can continue the activities that may make your pain worse. You should keep the stimulator on whilst you are in pain. There is no limit to the length of time the stimulator can be on. If you live locally you will be able to go home later on the day of your procedure. If you live a distance away then you will need to stay overnight.

You will return to the Pain Clinic for us to remove the lead and to determine whether or not the pain is relieved at all.

During your trial

You will need to remain lying down on the trolley or bed for 1 to 2 hours and gently mobilise for the rest of the day.

You should try to move around, getting back to your normality while being careful not to do too much in case the lead moves the next day and for the remainder of the trial. 

Ongoing

The injection site may be sore once the local anaesthetic has worn off. You can take painkillers for this.

  • The dressings should be kept dry and intact. 
  • Your activities need to be restricted to avoid the lead moving.
  • Do not raise your arms above your head.
  • Do not twist, bend or stretch at the waist. 
  • Do not lift heavy items.
  • Avoid sitting for long periods of time or driving a car.
  • Be careful not to catch the lead, make sure it is tucked inside your clothes and secured well to your body.

Stimulation 

If you are feeling  tingling this may increase when you bend back or when you lie down or sit. (Decrease the stimulation by lowering the amplitude). Stimulation may decrease when you stand up. (Increase the stimulation by increasing the amplitude). If the stimulation is uncomfortable at any time turn the stimulator off.

If you are at home for the trial and experience any of the following you should go to your nearest Accident and Emergency Department, or GP who will contact the Neurosurgical team:

  • Increasing severe pain in the back or neck.
  • New pain/weakness/numbness in the legs or arms.
  • Feeling unwell/flu-like symptoms/high temperature.

Stage two: permanent system

If the trial was a success then you will go on to have a full implant of the system. This may be performed under general anaesthetic/sedation or local anaesthetic. A small incision will be made in your back and the electrode will be implanted against your spinal cord. The connecting wire will be placed under the skin and attached to a battery. You will have a further incision in your skin either in your buttock or your abdomen to place the battery.

The stimulator is programmed post operatively and you will be able to go home the following day. The stimulation may not be as good immediately after this stage as when the temporary wire was in place but stimulation should improve over the next few weeks as healing takes place. The sutures or clips will be removed by the practice nurse 7 to 10 days after the operation.

Complications

As with all surgery there are a number of potential complications, some of which are fairly common:

  • Infection. Approximately 5% of cases. This would require the system being removed.
  • Bleeding.
  • Failure to relieve pain or increase in pain.
  • No stimulation or intermittent stimulation.
  • Headache.
  • Allergic reaction.
  • Stimulation in the wrong area.
  • Stimulation failure.
  • Nerve damage - rare.
  • Paralysis. This is very rare.

Following your implant of a spinal cord stimulator

You will remain in bed until the day following surgery and then start to gently mobilise. The Nurse Specialist or company technician will programme your stimulator and show you how to use your hand held programmer.  

You can use your programmer to:

  • Turn your generator on and off.
  • Increase and decrease the voltage within the 
    boundaries set.

The hand held programmers are expensive. We therefore advise that you have it insured. Please inform us if you have any problems with your programmer. 

What can I expect when I initially go home?

You may feel tired for about 2 to 4 weeks after the implant but it is important to build up you physical strength if possible by walking for brief periods of time each day.

You must tell your GP and Nurse Specialist if you notice any of the following, which may indicate an infection that needs treatment:

  • Any leakage from either wound. This may be brown, green or clear.
  • Redness or any swelling/pain at the wound site.
  • Any raised temperature.

For 4 to 6 weeks after implant it is important to avoid the following activities to prevent the lead from moving:

  • Avoid putting your arms above your head.
  • Try to avoid bending and twisting and lifting heavy weights.
  • Do not sit for too long in a chair.
  • Avoid driving for at least 2 weeks.
  • Do not operate motor vehicles, power tools or equipment while your stimulator is on. Turn the stimulator off to reduce safety risks associated with sudden sensation changes. 
  • Continue to take your normal pain medication for the first 6 weeks.  

General advice

  • Advice should be sought regarding Magnetic Resonance Imaging (MRI) as it can cause harm to you and the generator.
  • Diagnostic ultrasound is allowed but therapeutic ultrasound is not.
  • If you need further surgery you must tell the surgeon that you need BIPOLAR diathermy.
  • Stimulators may activate airport detectors and anti-theft devices in shops. These along with strong magnets can turn the generator off.
  • It is important to carry your identity card and programmer with you at all times.

Who will be responsible for my care?

After your permanent spinal cord stimulator has been implanted, you will not receive a routine follow-up in the joint pain neurosurgery clinic with Dr Love-Jones or Mr Williams. A phone follow up with the specialist nurses will be arranged and if any reprogramming is required this will be done by the Nurse specialists or company representatives. If you have a problem with your stimulator or you think it is not working properly then you can contact the Pain Clinic nurses on 0117 414 7379 and arrangements for assessment will be made.

If your GP would like any information you can give them the relevant contact details.

Contact details:

Nurse specialists  0117 414 7379

Mr Williams’ secretary 0117 414 6706

Dr Love-Jones’ secretary 0117 414 7364

It is very important that you inform us if you are taking any of the following anticoagulation/ blood thinning drugs before your procedure. These may include: warfarin, clexane, clopidogrel, rivaroxaban, dipyridamol, dabigatran.
Please note that this list is not exhaustive.

References

www.medtronic.co.uk
www.Bostonscientific.com
www.nice.org.uk
www.nevro.com 
www.abbott.co.uk
www.polarmedical.co.uk
NHS Constitution. Information on your rights and responsibilities. Available at: 
www.gov.uk/government/publications/the-nhs-constitution-for-england

© North Bristol NHS Trust. This edition published March 2024. Review due March 2027. NBT002348.